Exploring pharmacological interventions in benign prostate hyperplasia: the role of cost-effectiveness analysis in daily practice and future directions.
Expert Opin Pharmacother
; 25(7): 907-914, 2024 May.
Article
in En
| MEDLINE
| ID: mdl-38828638
ABSTRACT
INTRODUCTION:
Benign Prostate Hyperplasia (BPH) significantly impacts men's health and quality of life, with its prevalence rising with age. This review critically examines the cost-effectiveness of pharmacological interventions for BPH to optimize patient outcomes and healthcare resource utilization. AREAS COVERED This review explores the integration of cost-effectiveness analysis (CEA) into clinical practice, balancing clinical efficacy with economic efficiency in BPH management. We performed a critical literature search, including recent studies on the economic evaluation of BPH treatments, focusing on pharmacotherapies such as alpha-blockers and 5-alpha reductase inhibitors. Additionally, we discussed the concept of CEA and evaluated the role of medicinal reconciliation and the avoidance of polypharmacy in favor of optimal BPH treatment. EXPERT OPINION Cost-effectiveness analysis is crucial for evaluating BPH treatments, with evidence suggesting a shift towards surgical interventions may offer greater long-term economic benefits. However, these models must be applied cautiously, considering clinical evidence and patient preferences to ensure equitable and patient-centric healthcare.Key words
Full text:
1
Collection:
01-internacional
Database:
MEDLINE
Main subject:
Prostatic Hyperplasia
/
Quality of Life
/
Cost-Benefit Analysis
/
Adrenergic alpha-Antagonists
/
5-alpha Reductase Inhibitors
Limits:
Humans
/
Male
Language:
En
Journal:
Expert Opin Pharmacother
Journal subject:
FARMACOLOGIA
Year:
2024
Document type:
Article
Affiliation country:
Reino Unido